WellDoc, a Baltimore, MD-based developer of a FDA cleared mobile prescription therapy, raised $20m in financing.
Backers included Merck Global Health Innovation Fund and Windham Venture Partners.
The company intends to use the funds to launch and commercialize BlueStar, its mobile prescription therapy for type 2 diabetes, on a nationwide basis.
Led by Ryan Sysko, co-founder and CEO, WellDoc offers BlueStar, a patient-centered product cleared by the U.S. Food and Drug Administration in July 2010 for use by adults living with type 2 diabetes. BlueStar requires a prescription from a licensed healthcare provider and can be dispensed and reimbursed through a pharmacy.
It leverages the company’s proprietary Automated Expert Analytics System™ to enable patients to self-manage their diabetes through real-time motivational, behavioral and educational coaching.
FinSMEs
10/01/2014